T32

PHYSICIAN-SCIENTISTS UNDERREPRESENTED IN MEDICINE TO CONDUCT HEALTH EQUITY RESEARCH AT MONTEFIORE AND EINSTEIN

Retrieved on: 
Tuesday, February 6, 2024
Mortality, Hospital, Research, Obesity, Emotional intelligence, Montefiore Medical Center, HIV/AIDS, Pediatrics, Albert Einstein, Blood, Infant, Lung, Diversity, Epidemiology, National Institutes of Health, Sleep, Inclusion, Diabetes, Bangladesh Technical Education Board, Medicine, Health, Asthma, Montefiore, T32, Nursing

NEW YORK, Feb. 6, 2024 /PRNewswire/ -- Montefiore Health System and Albert Einstein College of Medicine have been awarded a $1.5 million National Institutes of Health grant to provide advanced research training to post-graduate trainees from groups that are underrepresented in medicine and have research interests in heart, lung, blood, and sleep disorders. Over five years, nine researchers will receive intense research training and robust mentorship from almost 30 established, senior investigators across Montefiore and Einstein.

Key Points: 
  • Over five years, nine researchers will receive intense research training and robust mentorship from almost 30 established, senior investigators across Montefiore and Einstein.
  • , principal investigator, vice chair for clinical and community-based research at the Children's Hospital at Montefiore and professor of pediatrics at Albert Einstein College of Medicine .
  • The research projects conducted by the nine investigators will aim to understand and reduce these inequities.
  • The T32 Training Program is titled "Purposeful Outreach for Diversity and Inclusion of Underrepresented in Medicine (PODIUM) Physician-Scientists" (1T32HL172255-01) and is intended to support training of postdoctoral trainees at Montefiore and Einstein, institutions uniquely positioned to engage minority and other health disparity populations in research, translation, and implementation of research advances that impact health outcomes, as well as provide health care for these populations.

CHOP Researchers Improve Fitness of Cells Used in Cell Transplants

Retrieved on: 
Wednesday, September 27, 2023
Hematopoietic stem cell transplantation, University, Blood, CHOP, HLA, Culture, Genomics, Gene editing, Proteomics, Research, Cell, T32, Child, Doctor of Philosophy, HSCT, EVS, Transplant, Seminal vesicles, Flow cytometry, MD, Patient, Risk, DOI, Sickle cell disease, Mouse, Hospital, NIH, Hematopathology, Safety, Children's Hospital of Philadelphia, Vaccine, EV, HSPC

PHILADELPHIA, Sept. 27, 2023 /PRNewswire/ -- A readily available, inexpensive small molecule drug can improve the fitness of hematopoietic stem and progenitor cells (HSPCs) that are modified outside of the body, potentially improving the success of procedures like ex vivo gene therapy, according to a new study by researchers at Children's Hospital of Philadelphia (CHOP). The study, published in the journal Blood, showed that targeting components in the cells called extracellular vesicles (EVs) relieves the stress on cells when outside of the body, improving their performance when they are transplanted back inside.

Key Points: 
  • Hematopoietic stem cell transplantation (HSCT) involves the transfer of HSPCs from a donor to patients with both benign and malignant diseases.
  • However, maintaining the fitness of these cells outside of the body poses a challenge, and any loss of fitness introduces the risk that the cells will not properly restore the blood and immune cell system in patients.
  • One process that we now learn contributes to cell equilibrium is the secretion of EVs, which are important for delivering messages from cell to cell and maintaining proper cell function.
  • "Neutral sphingomyelinase blockade enhances hematopoietic stem cell fitness through an integrated stress response," Blood, online Sept. 12, 2023, DOI: 10.1182/blood.2023022147

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Researchers Discover Potential Target for Gastric Cancers Associated with Epstein-Barr Virus

Retrieved on: 
Tuesday, August 22, 2023
DNA, Cell biology, Methylation, MBio, Hereditary diffuse gastric cancer, Collaborative writing, Cone Health Women's Hospital, Culture, Wistar, Infection, Cancer, Biomedical Research, Epstein–Barr virus, Research, Gene expression, Cell, T32, National Institutes of Health, Bangladesh Technical Education Board, Harvard Medical School, Ellen, Cytosine, Coriell Institute for Medical Research, Genome, Epigenome, Wistar Institute, Tempera, Hospital, DNA methylation, Stomach, P30, NIH, Medical research, EBV, Vaccine, Pharmaceutical industry, Decitabine, Brigham

PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .

Key Points: 
  • PHILADELPHIA, PA, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Now, scientists at The Wistar Institute have discovered a potential target for gastric cancers associated with Epstein-Barr Virus; study results were published in the journal mBio .
  • In the paper, Wistar’s Tempera lab investigates the epigenetic characteristics of gastric cancer associated with the Epstein-Barr Virus: EBVaGC.
  • "Normally, a latent virus that reactivates and starts to kill cells is a bad thing.
  • Because lysis is lethal to cells, the epigenetic reactivation of lysis within gastric cancer associated with EBV offers a promising potential treatment for the specific subset of EBVaGC.

Wistar Scientists Identify a Gene Signature to Assess Cancer Risk in People

Retrieved on: 
Monday, February 6, 2023
Online, Machine learning, Research, Culture, Marker beacon, Wistar Institute, Cancer, Infection, NIH, Cell biology, Molecule, Biomedical Research, Environment, TP53, T32, Vaccine, PNAS, Wistar

This does not help people determine whether they have increased cancer risk.

Key Points: 
  • This does not help people determine whether they have increased cancer risk.
  • This knowledge could be used to screen individuals with genetic variants of p53 and better inform them of their cancer risk and response to therapy.
  • Publication Information: Common activities and predictive gene signature identified for genetic hypomorphs of TP53.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.